绝经激素治疗与动静脉血栓栓塞性疾病  

Menopause hormone therapy and arteriovenous thromboembolism diseases

作　　者：史惠蓉[1] 李雪茹 贾艳艳[1] SHI Hui-rong;LI Xueru;JIA Yan-yan(Department of Gynecology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院妇科,河南郑州450052

出　　处：《中国实用妇科与产科杂志》2020年第3期224-227,共4页Chinese Journal of Practical Gynecology and Obstetrics

基　　金：河南省科技厅科技攻关项目(22170035/17)。

摘　　要：绝经激素治疗(MHT)是缓解女性更年期症状的重要医疗措施,但MHT也存在一定风险,其中,动静脉血栓栓塞性疾病包括静脉栓塞、肺栓塞、卒中的风险有可能增加。不同种类、不同途径应用MHT对人体的凝血、纤溶系统可产生不同的影响。MHT的治疗剂量、启动时间、持续时间、给药途径、用药方案以及孕激素的种类等所导致的血栓栓塞性疾病的风险不同。合理采用个体化MHT方案,有助于预防或降低动静脉血栓栓塞性疾病的相关风险。Menopause hormone therapy(MHT) is an effective therapeutic measure for climacteric symptoms.A large number of studies have shown that MHT is effective in relieving symptoms,but it also carries certain risks.The risk of arteriovenous thromboembolic diseases including venous embolism,pulmonary embolism and stroke may be increased.The administration of different kinds of hormones in different ways has different effects on coagulation and fibrinolysis system of the body.Therefore,the risk of thromboembolic diseases varies with different dose,initiation time,duration,route,regimens and progesterone types.Individualized menopausal hormone therapy should be used to prevent or reduce its related risks.

关 键 词：绝经激素治疗 静脉血栓栓塞症 缺血性卒中 

分 类 号：R711.75[医药卫生—妇产科学]